论文信息 - LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease - 字舞流文

LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease

W. Linehan | R. Srinivasan | W. Rathmell | E. Jonasch | J. Maranchie | S. Welsh | S. Oudard | V. Narayan | O. Iliopoulos | F. Donskov | R. Perini | T. Else | S. Thamake | B. Maughan | E. Park